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Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) delay progression ofmetastatic breast cancer. How-
ever, complete responses are uncommon and tumors eventually relapse. Here, we show that CDK4/6i can
enhance efficacy of T cell-based therapies, such as adoptive T cell transfer or T cell-activating antibodies
anti-OX40/anti-4-1BB, in murine breast cancer models. This effect is driven by the induction of chemokines
CCL5, CXCL9, and CXCL10 in CDK4/6i-treated tumor cells facilitating recruitment of activated CD8+ T cells,
but not Tregs, into the tumor. Mechanistically, chemokine induction is associated with metabolic stress that
CDK4/6i treatment induces in breast cancer cells. Despite the cell cycle arrest, CDK4/6i-treated cells retain
high metabolic activity driven by deregulated PI3K/mTOR pathway. This causes cell hypertrophy and in-
creases mitochondrial content/activity associated with oxidative stress and inflammatory stress response.
Our findings uncover a link between tumor metabolic vulnerabilities and anti-tumor immunity and support
further development of CDK4/6i and immunotherapy combinations.
INTRODUCTION
CDK4 and CDK6 are cell cycle kinases that work in complex with
cyclin D1 to phosphorylate tumor suppressor RB. Phosphoryla-
tion inhibits RB activity leading to its dissociation from E2F tran-
scription factors. Free E2Fs, in turn, transactivate genes involved
in DNA replication and cell cycle progression. Inhibitors of CDK4/
6 (CDK4/6i), such as palbociclib, ribociclib, and abemaciclib,
control tumor growth by blocking G1-to-S cell cycle transition
in cancer cells. CDK4/6i are used for treatment of recurrent
ER-positive, HER2-negative metastatic breast cancer (Cristofa-
nilli et al., 2016; Turner et al., 2018).
Interestingly, several studies indicated that, in addition to direct
effect on tumor cells, CDK4/6 inhibitors may influence immune
cells in the tumor microenvironment (Petroni et al., 2020; Teh
andAplin, 2019).This includessuppressionof regulatoryTcellpro-
liferation (Goel et al., 2017; Goel et al., 2016) and enhanced activa-
tion of tumor-infiltrating T cells (Deng et al., 2018; Schaer et al.,
2018). Furthermore, CDK4/6i treatment may affect tumor cells in
a way that may facilitate their recognition by the immune system
(Goel et al., 2017). Accordingly, CDK4/6i was shown to augment
immune checkpoint blockade therapy targeting PD-1/PD-L1 in
mouse models (Deng et al., 2018; Goel et al., 2017; Schaer et al.,
2018; Zhang et al., 2018).
These data suggest that CDK4/6i can promote activation of tu-
mor-infiltrating T cells (TILs). However, breast cancer tumors
often have low levels of TILs, which is referred to as ‘‘immunolog-
ically cold’’ tumor microenvironment. ‘‘Cold’’ tumors have ten-
dency to respond poorly to anti-PD-1 therapy (Cristescu et al.,
2018; Tumeh et al., 2014). Further, breast cancer patients with
low TILs often have worse survival and have limited response
to chemotherapy compared to patients with tumors that are
highly infiltrated with T cells (Dushyanthen et al., 2015). There-
fore, there is an unmet clinical need for therapeutic approaches
that can improve recruitment of T cells into the tumor.
Trafficking, localization, and positioning of T cells is regulated
by small proteins called chemokines (Chow and Luster, 2014).
Chemokines secreted by tumor cells and by non-malignant cells
within the tumor microenvironment (TME) play important role in
shaping tumor immune landscape (Vilgelm and Richmond,
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2019;Wellenstein and de Visser, 2018). A meta-analysis of 5,953
cancer specimens demonstrated positive correlation of CXCL9,
CXCL10, and CXCL11 expression with density of tumor-infil-
trating T and NK cells (Stoll et al., 2018). Similarly, CCR5 ligands,
CCL4 and CCL5, were shown to facilitate recruitment of several
anti-tumor immune cell types into the tumor including T cells and
BATF3-dependent dendritic cells (Böttcher et al., 2018;
Spranger et al., 2017; Vilgelm et al., 2015a). And vice versa,
low expression of CCR5 ligands (CCL3, CCL4, CCL5) and
CXCR3 ligands (CXCL9 and CXCL10) has been linked with
limited T cells infiltration (Harlin et al., 2009). Importantly, chemo-
kine expression is associated with effectiveness of immune
checkpoint therapy (e.g., anti-PD1 and anti-PD-L1), as reviewed
by Ayers et al. (2017) and Nagarsheth et al. (2017). Here, we
investigated the role of chemokines in CDK4/6i-mediated mod-
ulation of tumor immune microenvironment.
RESULTS
CDK4/6 inhibitor increases levels of T cells in mammary
tumors
We used a MMTV-PYMT murine mammary carcinoma model to
study the effect of CDK4/6i palbociclib on tumor immune micro-
environment. Transgenic MMTV-PYMT mice develop aggres-
sive metastatic mammary tumors between 8 and 12 weeks of
age (Guy et al., 1992) that recapitulate luminal BC subtype and
express ERa and progesterone receptor (PR) similarly to human
hormone receptor-positive luminal BC (Lin et al., 2003). Similar to
human BC, PYMT tumors are not highly immunogenic based on
virtually identical survival curves of PYMT mice on wild-type and
T cell-deficient (Rag/) backgrounds (DeNardo et al., 2009).
Here, we utilized a transplantable version of PYMT model where
PYMT tumor cells are inoculated into fourth mammary fat pads
of wild-type female C57BL/6 mice. Key experiments were
repeated using transgenicMMTV-PYMTmice (FVB background)
to determine whether our findings are consistent in distinct
model types (transplanted versus spontaneous) and genetic
backgrounds (C57BL/6 versus FVB).
We first verified that CDK4/6i palbociclib was effective in a
PYMT model. Transplanted PYMT tumors grew slower in pal-
bociclib-treated mice as compared to vehicle-treated animals
(Figure 1A). In agreement with cytostatic activity of CDK4/6i
(Klein et al., 2018; Knudsen and Witkiewicz, 2017), palbociclib
inhibited proliferation of tumor cells based on decreased Ki67
expression (Figures 1B and 1C). Similarly, the growth of spon-
taneous tumors arising in mammary glands of PYMT-FVB
transgenic mice was attenuated by palbociclib (Figure S1A).
Final tumor burden determined as combined weight of all tu-
mor lesions per mouse was reduced in the palbociclib group
(Figure S1B).
Flow cytometry immunophenotyping was done to determine
the effect of CDK4/6i treatment on the composition of tumor im-
mune microenvironment. To assess the temporal variations of
the CDK4/6i influence on immune profiles, as well as the effect
of tumor size, tumors were analyzed at early (8 days, comparable
size in the vehicle and CDK4/6i groups) and late (25 days,
reduced size in the CDK4/6i group) time points (arrows on Fig-
ure 1A indicate time points of tumor collection). Complete results
are shown in Table S1. The percentages of T cells were signifi-
cantly increased (p = 0.002) in tumors from CDK4/6i-treated
mice as compared to the vehicle group (Figures 1D and 1E; Table
S1) across both time points. There was no significant interaction
between treatment effect and day effect on T cell levels suggest-
ing that CDK4/6i-mediated increase of T cells was consistent
across tested time points and was not directly influenced by tu-
mor size. Among T cells, CD8+ T cells accumulated in CDK4/6i-
treated tumors (Figures 1D and 1E; Table S1). We also detected
an increase of B cells after palbociclib treatment; however, the
overall levels of B cells were low. Several immune populations
were differentially affected at early and late analysis time points,
Figure 1. CDK4/6i treatment increases the number and activity of T cells in mouse model of breast cancer
(A) Growth of PYMT tumors in female C57BL/6 mice treated twice daily with 100 mg/kg CDK4/6i palbociclib or vehicle (n = 20 mice/group, 10 mice/group
sacrificed at day 8, mixed-model statistics, data are represented as mean ± SEM). Arrows indicate days of tumor collection for immunophenotyping.
(B) Ki67 IHC staining in tumors from mice treated as in (A).
(C) Quantified percentages on Ki67+ cells in tumors frommice treated as in (A) (n = 3–5 individual tumors, t test, data are presented as individual values and mean
± SD).
(D) Representative plots from flow cytometry analysis of tumor-infiltrating immune cells frommice shown in (A). Tumors were collected at day 8 and 25. Cells were
gated on live CD45+ cells.
(E) Percentages of CD3+ and CD8+ cells in tumors from mice shown in (A) (n = 6–9 tumors/group, two-way ANOVA).
(F) Representative plots from flow cytometry analysis of phenotypes of tumor-infiltrating T cells frommice treated twice daily with vehicle or 100mg/kg palbociclib
for 10 days.
(G–I) Percentages on CD69+ (G), CD137+ (H), and CD134+ (I) CD8 T cells from the experiment shown in (F) (n = 5–6 tumors/group, t test). Cells were gated on live/
CD45+/CD3+/CD8+ population.
(J) Percentages of tumor-infiltrating Treg cells from the experiment in (F) (n = 5–6 tumors/group, t test). Cells were gated on live/CD45+/CD3+/CD4+ population.
(K) CD8/Treg cell ratios from the experiment shown in (F) (n = 5–6 tumors/group, t test).
(E–K) Data are presented as individual values and mean.
(L–N) Female C57BL/6 mice bearing PYMT tumors were treated twice daily with vehicle or 100 mg/kg CDK4/6i palbociclib. Mice were injected IP with 100 mg of
CD8-depleting or isotype control antibodies on day 2 post-palbociclib treatment initiation and every 2 days thereafter. Tumors were collected at day 10. There
were 6 mice (12 tumors) in each treatment group.
(L) Representative plots of flow cytometry analysis of CD8+ and CD4+ T cells in blood. Cells were gated on live/CD45+/CD3+ population.
(M) Percentages of CD8+ cells of total CD3+ T cells in blood (n = 4–5 mice/group, t test with Holm-Sidak correction, data are presented as individual values and
mean ± SD).
(N) Tumor growth over time (n = 12 tumors/group, mixed model, data are represented as mean ± SEM).
See also Figures S1 and S2 and Table S1.




whichmay reflect the role of time and size in shaping of tumor im-
mune landscape. For instance, the percentages of NK and NKT
significantly decreased from early to late time point; however,
they were not significantly affected by palbociclib. There were
also cell populations that were affected by palbociclib more
prominently as the time went by (treatment and day interaction),
such as tumor-associated macrophages, that were not dramat-
ically different at day 8, but were reduced at day 25 (Table S1).
The increase of tumor-infiltrating T cells, and, specifically,
CD8+ T cells, by CDK4/6i treatment was also detected in spon-
taneous tumors from transgenic PYMT FVB mice (Figure S1C),
indicating that the effect of CDK4/6i on T cells in consistent in
distinct models and genetic backgrounds. Notably, T cells
were infiltrating throughout the tumor in both injected (Fig-
ure S2A) and spontaneous (Figure S1D) models. The density of
T cells varied across tumor sections, with ‘‘hot’’ T cell-dense
areas present in some of the tested sections of CDK4/6i-treated
tumors (Figure S2A; Figure S1D).
We also characterized the effect of CDK4/6i on phenotype of
tumor-infiltrating T cells using spectral cytometry. A higher frac-
tion of tumor-infiltrating CD8+ T cells expressed activation
marker CD69 in CDK4/6i-treated mice as compared to the
vehicle cohort (Figures 1F and 1G). Furthermore, an increase in
the percentages of CD8+ T cells expressing co-stimulatory re-
ceptors CD137 (4-1BB) and CD134 (OX40) was observed after
CDK4/6i treatment (Figures 1F, 1H, and 1I). CDK4/6i decreased
the percentages of CD4 T cells expressing markers of T regula-
tory (Treg) cells, such as FoxP3+ and FoxP3+/CD25+ (Figures 1F
and 1J). Consequently, the CD8/Treg ratio was increased by
CDK4/6i treatment (Figure 1K). These data indicate that the
T cell infiltrate in CDK4/6i-treated tumors displays more promi-
nent anti-tumor phenotype compared to the vehicle cohort.
Dimension reduction analysis using tSNE showed a decrease
of the Treg cell cluster and an increase of active CD8+ T cell clus-
ter characterized by high expression of CD69, CD137, and
CD134 in CDK4/6i-treated tumors as compared to controls
(Figure S2B).
Of note, while PD-L1 expression on myeloid cells was not
significantly affected by CDK4/6i treatment (Table S1), we
observed an increase in the percentages of PD-L1 expressing
CD45-negative tumor cells from 1.3% in the vehicle group to
2.7% in the CDK4/6i treatment group (Figure S2C, p = 0.005).
Moreover, two out of six tumors in the CDK4/6i treatment group
had a proportion of CD45-negative tumor cells that lost MHCI
expression (Figure S2D). This effect may indicate compensatory
feedback response to increased T cell infiltrate in CDK4/6i-
treated tumors.
We next tested whether CD8+ T cells contributed to the overall
anti-tumor activity of CDK4/6i. PYMT tumor bearing mice were
treated with CDK4/6i or vehicle while also receiving injections
of CD8-depleting or isotype control antibody. Levels of periph-
eral CD8 T cells were prominently reduced by anti-CD8 treat-
ment (Figures 1L and 1M). CDK4/6i inhibited tumor growth in
both control and CD8+-depleted mice. However, tumor volumes
were smaller in CDK4/6i-treated mice that received isotype con-
trol antibodies as compared to CD8-depleted mice (Figure 1N).
These data suggest that anti-tumor activity of CDK4/6i was
partially dependent on CD8 T cells.
CDK4/6i treatment augments T cell-based therapies
We next tested whether increased levels of activated T cells in
CDK4/6i-treated tumors can be harnessed for cancer immuno-
therapy. Based on the increased expression of co-stimulatory
receptors OX40 and 4-1BB on T cells from CDK4/6i-treated tu-
mors, we hypothesized that CDK4/6i will sensitize tumors to an-
tibodies that activate these receptors. Of note, agonistic OX-40
and 4-1BB antibodies are currently in clinical development (Clin-
icalTrials.gov: NCT03364348 and NCT03217747). Mice inocu-
lated with PYMT cells were treated with vehicle or palbociclib
in the presence or absence of mouse-specific OX-40 and 4-
1BB agonistic antibodies. No significant inhibition of tumor
growth was evident after OX40/4-1BB stimulation in vehicle-
treated mice. In contrast, combining palbociclib with OX40/4-
1BB stimulation further reduced tumor growth as compared to
the palbociclib-only or vehicle treatment cohorts (Figure 2A).
Mice treated with palbociclib and anti-OX40/4-1BB displayed
the lowest final tumor weight at sacrifice (Figure 2B). We also
tested whether combined palbociclib and anti-OX40/4-1BB
therapy provided protection from tumor re-growth. PYMT-
bearing mice were treated with palbociclib and OX-40/4-1BB
antibodies for 25 days and monitored until their tumors reached
the end point size (15mm in diameter) or became perforated. The
fraction of surviving mice was numerically higher in palbociclib
and the anti-OX40/4-1BB combination treatment cohort; howev-
er, the differences were not statistically significant (p = 0.098)
(Figure 2C). Based on these data, we concluded that combining
palbociclib and endogenous T cell stimulation provides a
modest improvement of anti-tumor effect over single-agent
palbociclib.
We next evaluated whether CDK4/6i can augment anti-tumor
activity of adoptive cell therapy (ACT). The OT-1-OVAmodel was
used to recapitulate ACT conditions. PYMT tumor cells engi-
neered to express model antigen OVA were injected into female
C57BL/6 mice. When tumors formed, mice were treated with
vehicle or palbociclib for 2 weeks and then received injections
of OVA-specific T cells derived from spleens and lymph nodes
of OT-1 mice and activated ex vivo by CD3/CD28 stimulation
(Figure 2D). We first tested the recruitment of transferred
T cells into vehicle and CDK4/6i-treated tumors. OT-1 T cells
were fluorescently tagged prior to injection into mice to distin-
guish them from endogenous T cells. Tumors were analyzed
2 h post-injection (Figure 2D). We found that tumors from
CDK4/6i-treated mice recruited more T cells as compared to tu-
mors in vehicle-treated mice (Figure 2E). This suggests that
CDK4/6i promotes recruitment of transferred T cells into the
tumor.
We next investigated the impact of CDK4/6i on ACT efficacy.
Palbociclib and vehicle pre-treated mice that received either
mock injection or activated OT-1 T cells were monitored until
their tumors reached end-point size or became perforated.
Based on the first time point after T cell administration, palboci-
clib-treated mice that received mock injection had smaller
tumors that accelerated immediately after treatment discontinu-
ation. In contrast, tumors from palbociclib-treated mice that
received OT-1 T cells remained slow growing (Figure 2F). As a
result, mice in the combination treatment group exhibited
improved survival as compared to control vehicle-treated mice
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(Figure 2G, cf. black and purple lines). No significant survival
benefit was observed in the OT-1-only or CDK4/6i-only treat-
ment groups (Figure 2G). These data indicate that CDK4/6i
pre-treatment improved recruitment of exogenous T cells into
the tumor and augmented the outcome of ACT.
Chemokine receptors CCR5 and CXCR3 facilitate
CDK4/6i-mediated T cell recruitment
Immune cell trafficking and localization are regulated by chemo-
kine-chemokine receptor interactions. Activated T cells express
chemokine receptors CCR5 and CXCR3 that recognize chemo-
kines CCL5 and CXCL9, 10, and 11, respectively, secreted at the
sites of inflammation (Griffith et al., 2014). Therefore, we investi-
gated whether CCR5 and CXCR3 facilitated recruitment of
T cells into CDK4/6i-treated tumors by disabling these chemo-
kine receptors on T cells prior to injection. Neutralizing antibody
was used to block CXCR3. Incubation with high doses of CCL5
was used to inactivate CCR5. The latter causes internalization of
CCR5 that persists for at least 4 h after ligand withdrawal (Escola
et al., 2010). T cells were fluorescently labeled and transferred
into vehicle and CDK4/6i-treated C57BL/6 mice bearing
PYMT-OVA tumors (Figure 2H). Both CCL5 de-sensitization
and CXCR3 blockade abrogated homing of transferred T cells
into CDK4/6i-treated tumors (Figure 2I).
Based on these findings, we next asked whether CDK4/6i
treatment increased the levels of CCR5 and CXCR3 ligands at
the tumor site. Indeed, we found that tumors in CDK4/6i-treated
mice expressed higher levels of CCR5 ligand CCL5 and CXCR3
ligand CXCL9 as compared to controls (Figure 2J). To determine
whether malignant cells, rather than other cell types found within
the TME, upregulated chemokines in response to CDK4/6i, we
treated PYMT tumors cells with CDK4/6i palbociclib or vehicle
in vitro. CDK4/6i treatment upregulated CCL5 and CXCL9 in
PYMT cells onmRNA level (Figure 2K) and increased their secre-
tion into the culture medium (Figure 2L). These data suggest that
CDK4/6i treatment promoted secretion of inflammatory chemo-
kines by tumor cells resulting in improved CCR5 and CXCR3-
mediated homing of T cells into the tumor.
To determine whether chemokine-chemokine receptor inter-
actions played a role in CDK4/6i-mediated improvement of
ACT outcome, we administered OT-1 T cells to PYMT-OVA tu-
mor-bearing mice. Mice were pre-treated with CDK4/6i for
3 weeks (Figures 2F and 2G) and received treatments blocking
CCR5 and CXCR3-mediated trafficking. To block CCR5-CCL5
interaction, maraviroc was used, which is a small-molecule
antagonist of CCR5 (CCR5i). To inhibit CXCR3 function,
CXCR3-neutralizing antibody was administered in vivo. Control
mice received CDK4/6i and ACT only. Tumors in mice receiving
chemokine receptor blockade exhibited upward growth pat-
terns, while several tumors in the control cohort decreased or
stabilized after ACT administration. The overall growth was
significantly accelerated in maraviroc-treated mice (p = 0.008,
Figure 2. CDK4/6i improves immunotherapy response and promotes chemokine-mediated T cell tumor homing
(A) Tumor growth in C57BL/6 mice implanted with OVA-expressing PYMT tumor cells and treated with CDK4/6i palbociclib (100 mg/kg, twice a day), mix of
agonistic antibodies for OX-40 and 4-1BB (OX/BB, 100 mg each permouse, once every 3 days), a combination of both treatments, or vehicles for 25 days (n = 8–10
mice, two tumors per mouse, mixed-model statistics, data are represented as mean ± SEM).
(B) Final weight of tumors from experiment shown in (A) (n = 10–20 tumors, one-way ANOVA, data are presented as individual values and mean ± SD).
(C) Survival analysis in C57BL/6 mice implanted with OVA-expressing PYMT mammary tumor cells and treated as in (A) for 25 days and then followed till day 68
(n = 10 mice/group, Gehan-Breslow-Wilcoxon test).
(D) Schematic of T cell recruitment experiment. OVA-expressing PYMT cells were implanted in fourth mammary fat pad on female C57BL/6 mice. Mice were
treated once a day with 100 mg/kg palbociclib or vehicle for 2 weeks and then received an intravenous (i.v.) injection of OVA-specific T cells. T cells derived from
OT-1 mice were activated with anti-CD3/CD28 antibodies and fluorescently labeled ex vivo. Tumors were collected 2 h after cell transfer.
(E) Numbers of labeled T cells in tumors of C57BL/6mice from experiment described in (D) (n = 8 tumors/group, t test, data are presented as individual values and
mean ± SD).
(F) Tumor growth in C57BL/6 mice implanted with OVA-expressing PYMT mammary tumor cells and treated once a day with 100 mg/kg CDK4/6i palbociclib or
vehicle for 3 weeks followed by injection of OT-1 T cells or saline. Mice were followed until tumors reached end point size or became perforated (n = 7mice/group,
mixed model, data are represented as mean ± SEM).
(G) Survival analysis of mice from in (F). OT1 injection was given at day 25 (n = 7, log-rank [Mantel-Cox) statistical comparison between Vehicle and CDK4/6i+OT1
groups is shown). The experiment was repeated with consistent results.
(H) Scheme of an in vivo T cell recruitment experiment. C57BL/6 mice were inoculated with PYMT-OVA cells. Mice were treated with vehicle or CDK4/6i pal-
bociclib at 100 mg/kg for 25 days followed by i.v. injection of activated OT-1 T cells. To block CCR5 and CXCR3-mediated migration, OT-1 T cells were treated
with high dose of CCL5 or CXCR3-blocking antibody prior to transfer. T cells were labeled with cell tracker prior to injection into mice.
(I) Accumulation of fluorescent transferred T cells in PYMT tumors from experiment described in (L) (n = 5 mice/group, one-way ANOVA, data are presented as
individual values and mean ± SD).
(J) Real-time PCR analysis of CCL5 and CXCL10 mRNA in PYMT tumors from mice treated as in (A) (n = 3 tumors, t test after log transformation, data are
presented as individual values and mean ± SD).
(K) CCL5 and CXCL9 mRNA expression in PYMT tumor cells treated with vehicle or CDK4/6i (palbociclib, 1 mM) for 3 days in vitro (n = 2, t test, data are rep-
resented as mean ± SD).
(L) ELISA analysis of indicated chemokines in the conditioned medium of PYMT cells treated with vehicle or 1 mm palbociclib for 5 days (n = 2, t test, data are
represented as mean ± SD).
(M) Tumor volume change overtime with and without chemokine receptor blockade. Female C57BL/6 mice were implanted with PYMT-OVA tumors and treated
with palbociclib for 25 days and injected with activated OT-1 T cells (treatment scheduler was same as in F). A subgroup of mice received CCR5i maraviroc
(10 mg/kg, once daily oral gavage) or CXCR3-blocking antibody (200 mMper mouse, i.v. injection every 3 days) on days 25–42. Mixed model with Dunnett’s post-
test was used for statistical comparison of tumor growth between the control CDK4/6i+OT-1 group and chemokine-receptor-inhibited groups (n = 9 mice per
group, individual data presented). p value with and without adjustment for multiple comparison is shown for the CXCR3-blockade group.
(N) Survival curves from experiment in (M) (n = 9, log-rank (Mantel-Cox) statistical comparison between the CDK4/6i+OT1 and chemokine-receptor inhibited
groups).
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Figure 2M). CXCR3-inhibited mice exhibited similar trend; how-
ever, after adjusting the p value for multiple comparisons, the ef-
fect was not significant (adj. p = 0.08., raw p = 0.043, Figure 2M).
Notably, CCL5i-co-treated mice exhibited worse survival in
comparison to control (chemokine receptor-functional) mice
(Figure 2N). The effect of anti-CXCR3-treatement on survival
was not significant. Of note, 4 out of 9 mice survived over
90 days after ACT administration in the control group, as
compared to 1 out 9 mice in the chemokine receptor-inhibited
groups (Figure 2N). These data suggest that CDK4/6i-mediated
improvement of ACT efficacy is, at least in part, dependent on
chemokine receptors, especially CCR5.
CDK4/6i-treated human breast cancer cells produce
T cell-recruiting chemokines
We next investigated whether our mouse model findings were
relevant to human breast cancer. To test whether CDK4/6i
induced inflammatory chemokines in the human model, ER+
breast cancer cells MCF7 were treated with CDK4/6i or vehicle
control, and the levels of secreted chemokines were measured
in the conditioned media using a chemokine array. Several
chemokines were upregulated in CDK4/6i-treated cells,
including CCR5 ligand CCL5 and CXCR3 ligand CXCL10 (Fig-
ure 3A). Increased chemokine secretion was associated with
increased expression of chemokine mRNA indicating upregu-
lation on a transcriptional level (Figure 3B). Similar to
CXCL10, expression of two other CXCR3 ligands, CXCL9
and CXCL11, was increased after palbociclib treatment. We
confirmed that two other structurally distinct CDK4/6 inhibi-
tors, ribociclib and abemaciclib, also upregulated chemokines
in human breast cancer cells. In contrast, treatment with ro-
scovitin that inhibits CDK1/2/5/7/9, but not CDK4 or CDK6,
showed minimal effect on chemokine expression (Figure 3B).
This suggests that chemokine induction is an ‘‘on-target’’ ef-
fect of CDK4/6 inhibition. Chemokine induction was dose
dependent at the 3-day treatment time point with the level of
induction increasing progressively within the 0.1–10 mM range
of palbociclib concentrations (Figure 3C). Treatment was not
toxic at these conditions based on propidium iodide cytotox-
icity assay (Figures S3A and S3B).
Inactivating mutations/deletions of RB1 gene are associated
with CDK4/6i resistance (Álvarez-Fernández and Malumbres,
2020). Therefore, we tested whether chemokine induction by
palbociclib was linked with RB1 status. We tested the induction
of CCL5 by palbociclib in a panel of cell lines with wild-type and
deleted/mutated RB1. Information on RB1status was obtained
from cBIO portal (Cancer Cell Line Encyclopedia [CCLE] dataset)
(Cerami et al., 2012). Two- or greater fold induction of CCL5 was
detected in three tested RB1wild-type lines: MCF7, Cal120, and
MDA-MB-453 (Figure 3D). Two out of three RB1-altered lines
showed no significant CCL5 induction after CDK4/6i treatment.
Surprisingly, BT20 cells that have two amino acid substitutions
in RB1 protein, I338S and P515L, exhibited strong induction of
CCL5 mRNA after treatment with palbociclib. This induction
was likely on target because another CDK4/6i abemaciclib also
induced CCL5 in BT20 cells (Figure 3D, right panel). To investi-
gate this paradoxical activity further, we tested whether BT20 re-
sponded to CDK4/6i. Indeed, we found that cell numbers were
reduced in cultures of BT20 cells treated with different CDK4/6
inhibitors as compared to vehicle-treated cells (Figure 3E).
Furthermore, western blot analysis indicated reduction of the
CDK4/6-mediated inhibitory RB1 phosphorylation by CDK4/6i
treatment (Figure 3F). Based on these data, it is likely that the
specific RB1 genetic alterations found in BT20 cells were not
strongly detrimental to RB protein function, which is why these
cells responded to CDK4/6i. This conclusion is consistent with
data from other groups showing that BT20 cells are responsive
to palbociclib (Finn et al., 2009). Collectively, these data suggest
that CDK4/6i-mediated chemokine induction is linked with RB
inhibition.
Figure 3. CDK4/6i-treated breast cancer cells secrete chemokines associated with T cell infiltrate and favorable prognosis in breast cancer
patients
(A) Results of the cytokine array in conditioned media from MCF7 cells treated for 4 days with 1 mM palbociclib or vehicle control. Proteins elevated after pal-
bociclib (CDK4/6i) treatment are indicated with frames.
(B) Real-time PCR detection of CCL5, CXCL9, 10, 11mRNA inMCF7 cells treated with 1 mMpalbociclib, 3 mM ribociclib, 0.2 mMabemaciclib for 4 days. As a non-
CDK4/6i control, cells were treated with 10 mM roscovitin (n = 3, t test, data are represented as mean ± SD, *p < 0.05).
(C) Results of the real-time PCR analysis of CCL5, CXCL9, and CXCL10mRNA inMCF7 cells treated with palbociclib for 3 days at indicated concentrations (n = 3,
t test, *p < 0.05, data are presented as individual values, mean ± SD).
(D) Real-time PCR analysis of CCL5mRNA induction by palbociclib in six indicated cells lines with wild-type or alteredRB1 gene (n = 2–3, one-way ANOVA, (n = 3,
t test, data are represented as mean ± SD, *p < 0.05).
(E) Numbers of BT20 cells after 5 days of treatment with indicated CDK4/6 inhibitors or vehicle. Cells were stained with crystal violet and imaged in transmitted
light (n = 6, one-way ANOVA, data are presented as individual values and mean ± SD).
(F) Western blot analysis of the inhibition of RB1 hyper-phosphorylation in BT20 cells treated as described in (E).
(G) Real-time PCR detection of CCL5, CXCL9, and CXCL10 in MCF7 cells treated with 1 mMpalbociclib. Samples were collected at indicated time points ranging
from 8 h to 8 days. Solid lines represent samples that were continuously treated with palbociclib. Punctate lines indicate samples where palbociclib was removed
from culture media after day 5 of treatment.
(H) Numbers of crystal violet stained MCF7 cells treated as described in (G). Cells were treated with 1 mMpalbociclib for 8 days continuously or treated for 5 days
followed by drug washout and an additional 3 days of culture without drug. Control cells were treated with vehicle for 8 days (n = 3, one-way ANOVA, data are
presented as individual values and mean ± SD).
(I) Western blot analysis of RB phosphorylation in MCF7 cells treated as described in (G).
(J) Correlation of CCL5 (right panel) or CXCL10 (left panel) mRNA with CD8+ T cell infiltrate computed by CIBERSORT in TCGA set of luminal A breast cancer
tumors (N = 1,100).
(K) Comparison of overall survival in breast cancer patients with high expression of either CCL5, CXCL10, or both in their tumors (Z score > +1 [median ± 1 SD)) as
compared to the rest of the cases in TCGA breast cancer dataset (N = 1,093, log-rank test).
See also Figures S3 and S4.








Figure 4. mTOR-regulated metabolic activity is required for CDK4/6i-mediated chemokine induction
(A) RPPA proteomic profiling of MCF7 cells treated with vehicle or 5 mM CDK4/6i (Palbociclib) for 5 days. The heatmap shows proteins that passed the 1.5-fold
change and p < 0.05 (multiple t test) cutoff.
(B) Western blot validation of RPPA data.
(C) ELISA measurements of CL5 and CXCL10 in the conditioned medium of MCF7 cells treated with vehicle or 5 mM palbociclib ± 2 mM mTORi rapamycin for
5 days (n = 4 biological replicates pooled from 2 independent experiments, two-way ANOVA, individual data presented).
(D) ELISA measurements of CCL5 and CXCL10 in the conditioned medium of MCF7 cells treated with vehicle or 5 mM palbociclib ± 0.5 mM PI3Ki BKM120
(buparlisib) for 5 days (n = 3-6 biological replicates, one-way ANOVA, data are presented as individual values, mean ± SEM).
(E) Results of the luciferase-based glucose uptake assay in MCF7 cells treated with vehicle or 1 mM CDK4/6i palbocilib ± 2 mM mTORi rapamycin, or 0.5 mM of
PI3Ki BKM120 (buparlisib) for 5 days (n = 3 biological replicates, one-way ANOVA, data are presented as individual values and mean ± SD).
(legend continued on next page)




We also showed that the induction of CCL5 and CXCL9/10 in
response to CDK4/6i treatment was time dependent. The levels
of induction increased over time reaching a plateau around day 5
of continuous treatment (Figure 3G). Notably, cells that were
treated with palbociclib for 5 days continued to produce high
levels of chemokines when drug was removed from the culture
media (Figure 3G, punctate lines). The numbers of cells were
comparable after ‘‘5 days on + 3 days off’’ and ‘‘8 days on’’ treat-
ments (Figure 3H), suggesting that palbociclib-induced cell cycle
arrest was not immediately reversible. In agreement with this
conclusion, we detected an increased percentage of cells posi-
tive for senescence-associated b galactosidase (SA-bGal) after
5 days of CDK4/6i treatment (Figures S4A and S4B), which is a
marker of cellular senescence. Senescence is a type of persis-
tent growth arrest that occurs in response to a variety of
damaging conditions and is associated with increased secretion
of many factors, including pro-inflammatory chemokines CCL5
and CXCL9,10,11 (Vilgelm et al., 2019). In contrast to cell cycle
arrest, the levels of inhibitory RB1 phosphorylation showed full
recovery to the baseline levels after palbociclib withdrawal, indi-
cating reactivation of CDK4 and CDK6 (Figure 3I). Altogether
these data suggest that, although the effect of palbociclib on
CDK4/6 activity was reversible, the damage done to the cell dur-
ing the 5-day treatment was not. Since chemokine expression
was also not reversible, we concluded that chemokine induction
was not directly dependent in CDK4/6 activity but rather was
associated with cell damage induced by CDK4/6i treatment.
Chemokine expression is a favorable prognostic factor
in breast cancer patients
Our results showed that CDK4/6i induced chemokines in breast
cancer cells. Therefore, we sought to understand how elevated
chemokine expression may impact patients with breast cancer.
TIMER2.0 analysis of a TCGA dataset that included over a thou-
sand luminal A breast cancer samples (Li et al., 2020) demon-
strated strong association of CCL5 and CXCL10 expression
with CD8 T cell infiltrate estimated by CIBERSORT algorithm
(Figure 3J). Furthermore, breast cancer patients with elevated
expression of CCL5 and CXCL10 in their tumors (defined by a
Z score threshold of ±1 SD) exhibited improved overall survival
in comparison to patients with low-to-moderate chemokine
expression (Figure 3K). These data suggest that increased che-
mokine expression in CDK4/6i-treated tumors can have benefi-
cial effect on patients’ outcome.
CDK4/6i inhibits expression of cell cycle mediators
while promoting mTOR activity
We next investigated the mechanism of CDK4/6-mediated che-
mokine induction. Palbociclib- and vehicle-treated MCF7 cells
were subjected to reverse phase protein array (RPPA) analysis
that detects expression of 471 proteins and phosphoproteins.
Proteins that were significantly up- or downregulated after
CDK4/6i treatment are presented on a heatmap (Figure 4A).
Compete RPPA data are provided in Table S2. As expected,
we observed downregulation of proliferation-related proteins
(phosphorylated RB, cyclin B1, Wee1, PLK1, etc.) along with up-
regulation of cell cycle arrest inducer p21 in CDK4/6i-treated
cells (Figure 4A, blue frames). One pattern that caught our atten-
tion was the increased phosphorylation of mTOR kinase targets,
such as S6, p70-S6K, and ULK1 in CDK4/6i-treated cells (Fig-
ure 4A, red frames). Western blot analysis confirmed increased
phosphorylation of S6 on residues S240-244, and S235-236,
and 70-S6K on T389 after CDK4/6i treatment (Figure 4B). These
changes are indicative of the mammalian target of rapamycin
complex 1 (mTORC1) activity (Liu and Sabatini, 2020).
A number of prior studies showed the requirement of mTOR
for chemokine induction in some immune cell subsets, such as
monocytes and macrophages (Jin and Zhao, 2020; Lin et al.,
2014; William et al., 2019). Therefore, we investigated whether
mTOR was similarly involved in chemokine induction in breast
cancer cells treated with CDK4/6i. MCF7 cells were treated
with vehicle or palbociclib in the presence or absence of
mTOR inhibitor rapamycin. We found that CDK4/6i-induced
secretion of CCL5 and CXCL10 was abrogated in the presence
of mTOR inhibitor, suggesting that mTOR activity was necessary
for chemokine induction (Figure 4C). Similarly, inhibition of up-
stream mTOR activator PI3K (Laplante and Sabatini, 2012) with
a small-molecule inhibitor BKM120 (buparlisib) abolished che-
mokine induction by CDK4/6i (Figure 4D). In agreement with
these experimental findings, cBIO analysis of the TCGA dataset
of 960 breast carcinoma specimens showed higher content of
mTOR activity marker phosphorylated S6 protein (residues
S235/S236 and S240/S244) in tumors with elevated CCL5 and
CXCL10 expression (Figure S5A).
Prior studies indicated that targeting PI3K/mTOR pathway in
the context of CDK4/6i treatment could improve tumor growth
inhibition and prevent acquisition of resistance via tumor intrinsic
mechanisms (O’Brien et al., 2020; Vilgelm et al., 2019; Yoshida
et al., 2019). However, these preclinical studies used immunode-
ficient mice lacking T cells. Here, we tested how combined
CDK4/6 and mTOR inhibition affects tumor growth and immune
infiltrate in immunocompetent model. Female C57BL/6 mice
were injected with PYMT tumor cells and treated with vehicle,
CDK4/6i palbociclib, mTOR inhibitor everolimus (currently used
for treatment of human breast cancer), or a combination of
both drugs (Figure S5B). Tumor growth wasmost prominently in-
hibited in the CDK4/6i andmTORi combination group. There was
a significant benefit of combining CDK4/6i with mTORi over
CDK4/6i single agent (p = 0.048) but not over single-agent
mTORi (p = 0.094). Flow cytometry analysis indicated a decrease
of CD3+ T cells, including CD8+ T cells, in the CDK4/6i and
mTORi combination group as compared to CDK4/6i single agent
(F) Same as (E) except intracellular glutamate was measured.
(G) Schematic of the experimental approach to block glucose and glutamine uptake for the experiment in (H).
(H) ELISA measurements of CCL5 and CXCL10 in the conditioned media from MCF cells treated for 5 days with 5 mM CDK4/6i palbociclib in the presence or
absence of pharmacological inhibitors of glucose (1 mM Bay876, GLUTi) or glutamine (10 mM O-Benzyl-L-Serine, ASCTi) transporters (n = 3-6 biological rep-
licates, two-way ANOVA, data are presented as individual values and mean).
See also Figure S5 and Table S2.
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(Figure S5C). Considering the critical role of mTOR in immune
system function (Weichhart et al., 2015), themechanism of tumor
immunome modulation by the mTORi is likely complex. Thus,
while our results are in agreement with mTOR being a promising
co-target in the context of CDK4/6i treatment, they also indicate
that mTORi co-targeting may not be advisable in situations when
T cell-enriched microenvironment is desired (i.e., if immuno-
therapy is planned). Dedicated future studies will be required
to address the complex role of mTOR in anti-tumor immunity.
mTOR-regulated metabolic activity is required for
CDK4/6i-mediated chemokine induction
We next sought to determine how mTOR regulated chemokine
expression in CDK4/6i-treated cells. mTOR is a central regulator
of cell metabolism (Sabatini, 2017; Saxton and Sabatini, 2017).
Therefore, we investigated whether CDK4/6i-treated cells were
metabolically active. RPPA indicated upregulation of a number
of metabolism-associate proteins in CDK4/6i-treated cells
including hexokinase I (HK1), glycogen synthase (Gys), and
glucose-6-phospate dehydrogenase (G6PD) (Figure 4A, orange
frames). However, some metabolic proteins were differentially
affected by CDK4/6i. For instance, a mediator of serine meta-
bolism PHGDH was downregulated by palbociclib (Figure 4A).
To further investigate the effect of CDK4/6i on cell metabolic
activity, we measured glucose uptake and glutamine utilization
in vehicle and palbociclib-treated MCF7 cells. Glucose and
glutamine are critical nutrients required for cancer cell growth
and their consumption reflects cell’s metabolic demands.
Notably, CDK4/6i treatment did not inhibit nutrient consumption
(Figures 4D and 4E). In fact, the levels of intracellular glutamate, a
product of glutamine conversion within the cells, was increased
in CDK4/6i-treated cells as compared to vehicle-treated cells
(Figure 4E). Furthermore, inhibition of mTOR or its upstream
regulator PI3K down-modulated glucose uptake and glutamine
utilization in CDK4/6i-treated cells. These data suggest that
mTOR is required to maintain metabolic activity in CDK4/6i-
treated cells. To test whether maintenance of high metabolic ac-
tivity played role in CDK4/6-mediated chemokine induction, we
blocked nutrient uptake in breast cancer cells using pharmaco-
logical inhibitors of glucose transporter GLUT (GLUTi Bay876) or
glutamine transporter ASCT2 (and O-benzyl-L-serine, respec-
tively) (Figure 4F). Both inhibitors abrogated CCL5 and
CXCL10 induction after CDK4/6i treatment (Figure 4G).
CDK4/6i-mediated chemokine production is associated
with cell hypertrophy, accumulation of mitochondria,
and induction of ROS
Generally, active metabolism and high mTOR activity are char-
acteristics of fast proliferating cells. Indeed, mTOR promotes
anabolic metabolism and biosynthesis to coordinate cell division
with doubling of cell biomass and organelle biogenesis. Quies-
cence cells often inactivate the mTOR kinase due to the lack of
need for cell growth (Valcourt et al., 2012). Therefore, we were
surprised to detect activation of mTOR and metabolism in cells
treatedwith CDK4/6i that inhibits proliferation. Hence, we sought
to understand how increased metabolic activity was utilized in
CDK4/6i-treated cells. We found that palbociclib treatment
caused cell hypertrophy in breast cancer lines (Figure 5A). An in-
crease in cell sizes after palbociclib was confirmed by flow cy-
tometry (Figure 5B). Cell growth phenotype was driven by
PI3K/mTOR pathway as pharmacological inhibition of either
mTOR or PI3K abrogated CDK4/6i-mediated cell size increase
(Figure 5B; Figure S5F). CDK4/6i-treated cells also exhibited
an increase of the cell complexity as per flow cytometry analysis,
which indicates increased organelle content. Similar to the
increased size, increased complexity was alleviated by mTOR
and PI3K inhibition (Figure 5C). We next investigated whether
mitochondria were among the organelles accumulating in
CDK4/6i-treated cells based onmTORbeing a key driver ofmito-
chondrial biogenesis (Morita et al., 2013). Indeed, mitochondrial
content was increased in cells treated with CDK4/6i based on
mitotracker staining detected by microscopy (Figure 5D) and
flow cytometry (Figure 5E). To test whether mitochondria were
functional in CDK4/6i-treated cells, we used a JC-1 mitochon-
drial potential probe. JC-1 forms aggregates in healthy polarized
mitochondria that emit red fluorescence. Cells with depolarized
Figure 5. CDK4/6i-mediated chemokine production is associatedwith cell hypertrophy, accumulation ofmitochondria, and induction of ROS
(A) Microscopic images of crystal violet stained cells that were treated for 5 days with 5 mM of palbociclib, except for BT20, which were treated with 1 mM
palbociclib.
(B) Flow cytometry measurement of forward-scattered light (FCS) parameter indicative of cell volume. MCF7 cells treated with vehicle or 1 mMpalbociclib ± 2 mM
mTORi rapamycin, or 0.5 mM of PI3Ki BKM120 (buparlisib) for 5 days (n = 3, one-way ANOVA, data are presented as individual values and mean).
(C) Same as (F), except side-scattered light (SSC) channel signals indicative of cell complexity (presence of granules and organelles) are shown.
(D) Fluorescent microscopy of mitochondria detected with MitoTracker Green in MCF7 cells treated with vehicle or 5 mM CDK4/6i palbociclib for 5 days.
(E) Quantification of the MitoTracker staining shown in (D) using flow cytometry (n = 6–8, one-way ANOVA, data are presented as individual values and mean).
(F) Mitochondrial potential analysis using JC-1 biosensor. Red punctate signal, aggregates of JC-1 in polarized mitochondria; green cytoplasmic staining, free
JC-1 monomers. Random microscopic fields from 4 biological replicates quantified with ImageJ (n = 19–20, t test, data are presented as individual values and
mean).
(G) Representative fluorescence microscopy images of cellular ROS detected with CellROX Deep Red in MCF7 cells treated with vehicle or 5 mM palbociclib
(CDK4/6i) for 5 days. Right panel shows average values of ROS fluorescence per cell from 4 biological replicates compared using t test. Data are presented as
individual values, mean ± SD.
(H) Representative histogram (left panel) from flow cytometry analysis of cellular ROS in MCF7 cells treated with vehicle or 5 mM CDK4/6i palbociclib for 5 days.
Right panel shows quantified data (n = 3, t test, data are presented as individual values, mean ± SEM).
(I) Levels of chemokines CCL5 and CXCL10 in the conditioned media from MCF7 cells treated with 5 mM of cellular ROS scavenger NAC, CDK4/6i (5 mM),
combination of both, or vehicle for 5 days (n = 4–6, one-way ANOVA, data are presented as individual values, mean ± SEM).
(J) Proposed model CDK4/6i-mediated chemokine induction. Briefly, the PI3K/mTOR pathway remains active in CDK4/6i-treated cells despite the decreased
metabolic demands due to the cell cycle arrest. This leads to exacerbated cell growth and mitochondrial levels and activity associated with oxidative stress,
which, in turn, promotes production of T cell-recruiting chemokines.




mitochondria exhibit loss of a red punctate fluorescence and in-
crease of diffuse green fluorescence from JC-1 monomers
diffused in the cytoplasm. We detected strong red fluorescence
in both vehicle and CDK4/6i-treated cells. Furthermore, red/
green ratio was further increased after CDK4/6i treatment indi-
cating high mitochondrial activity (Figure 5F).
Mitochondria are a key source of intracellular ROS (Scialò
et al., 2017). Furthermore, CDK4/6i has been shown to induce
ROS in pancreatic cancer cells as a result of mTOR-mediated in-
crease of glycolytic and oxidative metabolism andmitochondrial
content (Franco et al., 2016), and we observed similar metabolic
changes here in a model of breast cancer. Accordingly, we de-
tected increased ROS levels after 5-day palbociclib treatment
by fluorescencemicroscopy (Figure 5G) and flow cytometry (Fig-
ure 5H). ROS is a potent pro-inflammatory signal known to
induce expression of chemokines and other inflammatory medi-
ators (Sozzani et al., 2005). Therefore, we next evaluated
whether ROS was involved in CDK4/6i-induced chemokine
secretion. We measured cellular ROS production in MCF7 cells
and found it to be increased after 5 days of palbociclib treatment.
Removal of ROS using ROS scavenger N-acetylcysteine (NAC)
completely abrogated CDK4/6i-mediated chemokine produc-
tion (Figure 5I). These data suggest that CDK4/6i-mediated che-
mokine induction in breast cancer cells requires ROS.
Collectively our data suggest that palbociclib inhibited cell cy-
cle arrest without concurrently shutting down cell metabolism.
Cells continued to uptake nutrients to supply energy/building
blocks for mTOR-driven biosynthesis. The uncoupling of meta-
bolic need and supplymanifested in increased cell size andmito-
chondrial biogenesis and activity associated with accumulation
of ROS, which, in turn, induced inflammatory chemokines that
recruited T cells into the tumor (Figure 5J).
DISCUSSION
Here, we show that CDK4/6i palbociclib promotes recruitment of
T cells into mammary tumors by inducing expression of T cell-
chemotactic chemokines in tumor cells. This finding has several
clinical implications. First, the ability of CDK4/6i to enhance T cell
tumor homing could make these agents useful for sensitizing pa-
tients to T cell-delivering therapies such as adoptive cell transfer
of T cells and CAR T cells. Indeed, our pre-clinical model showed
that CDK4/6i pre-treatment improved outcome and survival of
mice that received transfer of activated tumor-specific T cells.
Second, TCGA analysis showed that increased expression of
chemokines CCL5 and CXCL10, which are induced by CDK4/
6i, is an overall positive prognostic factor in breast cancer.
Furthermore, recently published expression analysis of breast
cancers tumors before and after treatment with CDK4/6i abema-
ciclib and aromatize inhibitor anastrosole (neoMONARCH study)
showed CCL5 induction and overall enrichment of the chemo-
kine/chemokine receptor expression signature after CDK4/6i
treatment (Hurvitz et al., 2020), which is in agreement with our
mouse model findings.
The present study uncovered the mechanism of CDK4/6i-
mediated chemokine induction. We found it to be dependent
on metabolic alterations that occurred in cells after CDK4/6i
treatment. These changes included activation of mTOR,
induction of glucose and glutamine metabolism accompanied
by the increase in cell size and mitochondrial/lysosomal content.
Metabolic activation after CDK4/6i treatment was reported pre-
viously (Warth et al., 2019; Warth et al., 2018; Zanuy et al., 2012).
For example, CDK4/6i-treated pancreatic cancer cells exhibited
accumulation of ATP, increased mitochondrial mass, activation
of glycolytic, and oxidative metabolism driven by themTOR acti-
vation (Franco et al., 2016). Similarly, Cretella et al. (2018)
showed that CDK4/6i treatment activated PI3K/AKT/mTOR
pathway in TNBC cells, and co-inhibition of this pathway
impaired glucose metabolism (Cretella et al., 2018). Inhibition
of CDK4/6 with siRNA or specific pharmacologic inhibitor
increased glutamine metabolism, mitochondrial content, and
mTOR pathway activity in colon cancer cells (Tarrado-Castellar-
nau et al., 2017). Activation of mTOR was also reported in mela-
noma PDXs and in patients treated with CDK4/6i (Teh et al.,
2018; Vilgelm et al., 2019). Here, we showed that mTOR-medi-
ated metabolic reprogramming was critical for CDK4/6i-medi-
ated chemokine induction. Blockade of metabolism by inhibiting
the uptake of two key nutrients consumed by proliferating cancer
cells, glucose and glutamine, inhibited CDK4/6i-mediated che-
mokine production.
Cell cycle machinery and metabolism are interconnected.
Proliferating cells display high metabolic activity that ensures
availability of metabolites for DNA synthesis and cell growth.
This is in contrast to quiescent cells that have low metabolic de-
mands (Valcourt et al., 2012). Surprisingly, despite being in a
state of cell cycle arrest, CDK4/6i-treated breast cancer cells
displayed phenotype of active metabolism. Thus, we postulated
that excessive metabolic activity caused metabolic stress in
CDK4/6i-treated cells due to nutrient excess. This could be anal-
ogous to chronic organismal over-nutrition (obesity), which can
lead to various pathological conditions (Wellen and Thompson,
2010). One of the key markers of metabolic stress induced by
nutrient excess is an excessive production of ROS and oxidative
stress (Wellen and Thompson, 2010). Accordingly, we found
increased ROS content in CDK4/6i-treated cells, which was
required for CDK4/6i-mediated chemokine production. Further-
more, CDK4/6i inducedmitochondria content and activity, which
are the major source intracellular ROS (Gogvadze et al., 2008).
Oxidative stress is a key link between metabolic stress and in-
flammatory stress response. For instance, ROS has been impli-
cated as a key driver of chronic inflammation in many diseases
associated with metabolic dysfunction, including atheroscle-
rosis, diabetes mellitus, and stroke (Forrester et al., 2018).
ROS play important role in regulation of inflammatory response
associated with activation of pattern recognition receptors, nu-
clear factor kB (NF-kB), and inflammasome (Forrester et al.,
2018; Lugrin et al., 2014). Moreover, ROS are required for normal
function of innate and adaptive immune cells, which further un-
derlines their role as a key immune mediator (Chen et al., 2018;
Kohchi et al., 2009; Yarosz and Chang, 2018). It is plausible
that the biological significance of ROS-mediated induction of
chemokines in context of CDK4/6i treatment is to alert the
immune system of cell damage. Indeed, excessive ROS can
damage cellular DNA leading tomutations that pose risk of onco-
genic transformation; therefore, immune recognition of such
cells can be beneficial.




Our data highlight an important role of inflammatory chemo-
kines produced by malignant cells in regulation of the composi-
tion of tumor immune microenvironment, immunotherapy
response, and patient outcome. One can envision T cell recruit-
ing chemokines being useful as prognostic markers for patient
stratification for immunotherapy treatment. Furthermore, with
the advancement of the circulating tumor cell technology, longi-
tudinal assessment of chemokine expression in tumor cell can
be performed. This type of analysis can identify the perfect win-
dow for second hit immunotherapy administration in patients
treated with CDK4/6i or other agents that induce chemokine
expression in tumor cells, such as senescence-inducing drugs
and epigenetic modulators (Dangaj et al., 2019; Vilgelm et al.,
2015b, 2016). The findings presented here raise a possibility of
utilizing CDK4/6 inhibitors to enhance anti-tumor immunity and
immunotherapy response in ‘‘cold’’ T cell-excluded tumors.
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Antibodies
CD45 BioLegend 103116; RRID:AB_312981
CD3 Fisher 460032-80; RRID:AB_1834428
CD4 BioLegend 100438; RRID:AB_11203718
CD8 BioLegend 100712; RRID:AB_312751
NK1.1 BioLegend 108708; RRID:AB_313395
CD19 Miltenyi 130-105-171; RRID:AB_2661109
CD44 BioLegend 103025; RRID:AB_493712
CD62L BioLegend 104417; RRID:AB_313102
TIM3 BioLegend 119721; RRID:AB_2616907
LAG3 BioLegend 125219; RRID:AB_2566571
CXCR3 BioLegend 126531; RRID:AB_2563160
CD8a Thermofisher 46-0081-82; RRID:AB_1834433
CD11C BioLegend 117330; RRID:AB_11219593
F4/80 Thermofisher 17-4801-80; RRID:AB_2784647
CD206 BioLegend 141705; RRID:AB_10896421
CD11b BioLegend 101217; RRID:AB_389305
I-A/I-E BioLegend 107622; RRID:AB_493727
Ly6G BioLegend 127617; RRID:AB_1877262
Ly-6C BioLegend 128035; RRID:AB_2562352
CD103 BD 564322; RRID:AB_2738744
PD-L1 BD 740614; RRID:AB_2740313
CD45 BD 564279; RRID:AB_2651134
CD69 Invitrogen 11-0691-85; RRID:AB_465120
FOXP3 BioLegend 126404; RRID:AB_1089117
CD25 Invitrogen 56-0251-80; RRID:AB_891424
MHC Class I Invitrogen 25-5958-80; RRID:AB_2573504
CD137 Invitrogen 46-1371-80; RRID:AB_2573713
CD134 BD 740945; RRID:AB_2740573
CD3e BD 563024; RRID:AB_2737959
CD8 BioLegend 100712; RRID:AB_312751
CD11b BioLegend 101267; RRID:AB_2810328
CD8-depleting antibody (YTS 169.4) BioXcell (West Lebanon, NH) BP0117; RRID:AB_10950145
Anti-OX-40 (OX-86) BioXcell (West Lebanon, NH) BE0031; RRID:AB_1107592
Anti-4-1BB (LOB12.3) BioXcell (West Lebanon, NH) BP0169; RRID:AB_10949016
Purified anti-mouse CD183 (CXCR3) Biolegend 126502; RRID:AB_1027635
Anti-CD3e Biolegend 100302; RRID:AB_312667
Anti-CD28 Biolegend 102102; RRID:AB_312867
Anti-mouse CD16/32 Biolegend 156604; RRID:AB_2783138
RB1 Cell signaling 9309S; RRID:AB_823629
Phospho- RB (S807/S811) rabbit antibody Cell signaling 8516S; RRID:AB_11178658
S6 Ribosomal protein rabbit antibody Cell signaling 2217S; RRID:AB_331355
Phospho-S6 (S235/236) Ribosomal protein
rabbit antibody
Cell signaling 2211S; RRID:AB_331679
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Phospho-S6 (S240/244) ribosomal protein
rabbit antibody
Cell signaling 5364; RRID:AB_10694233
Phospho-p70 S6 (T389) kinase rabbit
antibody
Cell signaling 9234; RRID:AB_2269803
p70 S6 kinase rabbit antibody Cell signaling 2708; RRID:AB_390722
p21 Waf1/Cip1 rabbit antibody Cell signaling 2947S; RRID:AB_823586
b-actin rabbit antibody Cell signaling 4970S; RRID:AB_2223172
b-tubulin rabbit antibody Cell signaling 2146S; RRID:AB_2210545
HSP90 rabbit antibody Cell signaling 4874S; RRID:AB_2121214
Chemicals, peptides, and recombinant proteins
Dulbecco’s modified Eagle’s medium/F12 GIBCO 11330032
GlutaMAX GIBCO 35050061
GIBCO Penicillin-Streptomycin GIBCO 15-140-122
Fetal Bovine Serum GIBCO 16000036
Palbociclib Pfizer N/A







CellTracker Green CMFDA Dye Invitrogen C2925
Murine recombinant CCL5 Peprotech 25007
MitoTracker Green Invitrogen T7514
CellRox Deep Red Invitrogen C10422
LysoTracker Deep Red Invitrogen L12492
DAPI Invitrogen D1306
Hoechst 33342 Invitrogen H1399
JC-1 Mitochondrial Membrane Potential
Dye
Thermo Fisher 3168
Fixable Viability Dye eFluor 780 Invitrogen 65-0865-14
LIVE/DEAD Fixable Aqua Dead Cell Stain
Kit
Thermofisher L34957
Everolimus LC Laboratories E-4040
10X Tris/Glycine/SDS Buffer Biorad 1610772
Tris Buffer Saline Fisher Bioreagents BP2471-1
Tween 20 Fisher Bioreagents BP 337-500
Trans Blot Turbo RTA transfer kit Biorad 170-4270
Bovine serum Albumin Fisher Bioreagents BP9706-100
Protein assay dye reagent concentrate Biorad 5000006
Critical commercial assays
Reverse Phase Protein Array (RPPA) Core Facility at MD Anderson
Cancer Center (Houston, TX)
N/A
RNA-easy mini kit QIAGEN 74104
iScript cDNA synthesis kit BioRad 1708890
Quantiline ELISA HumanCXCL10/IP-10 R&D system DIP100
Quantiline ELISA Human CCL5/RANTES R%D system DRN00B
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Tumor tissue dissociation kit Miltenyi Biotech 130-096-730
FXP3/ Transcription Factor Staining Buffer
Set
Invitrogen 00-5523-00
SYBR-green master mix BioRad 1725270
Senescence b-Galactosidase Staining Kit Sigma CS0030
Experimental models: Cell lines
MCF7 Cell line American Type Culture Collection ATCC HTB22
Cal120 cell line Carlos L. Arteaga Vanderbilt-Ingram
Cancer Center.
N/A
MDA-MB-453 cell line Carlos L. Arteaga Vanderbilt-Ingram
Cancer Center.
N/A
MDA-MB-468 cell line Carlos L. Arteaga Vanderbilt-Ingram
Cancer Center.
N/A
HCC70 cell line Carlos L. Arteaga Vanderbilt-Ingram
Cancer Center.
N/A
BT20 cell line Carlos L. Arteaga Vanderbilt-Ingram
Cancer Center.
N/A
PYMT cell line Philip Owens (VA Eastern Colorado
Health Care System, Denver, CO)
N/A
PYMT-OVA cell line David DeNardo (Washington University St.
Louis, St. Louis MO)
N/A
Experimental models: Organisms/strains
C57BL/6 mice The Jackson Laboratory 000664
C57BL/6 mice Charles River/NCI Strain code:027
OT-1 mice Marc Boothby, Richard O’Neil (Vanderbilt
University, Nashville, TN)
N/A
OT-1 mice The Jackson Laboratory 003831




Primer: h CXCL10 F
GTGGCATTCAAGGAGTACCTC
Sigma N/A
Primer: h CXCL10 R
TGATGGCCTTCGATTCTGGATT
Sigma N/A
Primer: h CXCL9 F
CCAGTAGTGAGAAAGGGTCGC
Sigma N/A
Primer: h CXCL9 R
AGGGCTTGGGGCAAATTGTT
Sigma N/A
Primer: m CXCL9 F
GGAGTTCGAGGAACCCTA
Sigma N/A
Primer: m CXCL9 R
GGGATTTGTAGTAGTGGATCGTGC
Sigma N/A
Primer: m CCL5 F
GCTGCTTTGCCTACCTCTCC
Sigma N/A
Primer: m CCL5 R
TCGAGTGACAAACACGACTGC
Sigma N/A
Primer: h CCL5 F
CCAGCAGTCGTCTTTGTCAC
Sigma N/A
Primer: h CCL5 R
CTCTGGGTTGGCACACACTT
Sigma N/A
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Further information and requests for all original resources and reagents presented in this manuscript should be directed to andwill be
fulfilled by the Lead contact, Anna Vilgelm (anna.vilgelm@osumc.edu).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The published article includes all datasets generated during this study. Original data for Figure 4A is available in supplemental
spreadsheet 1.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All animal experiments were approved by Vanderbilt University and the Ohio State University IACUC. Female mice were used in this
study as breast cancer primarily affects female population. For transplantedmodel, mice were 7-14 weeks of age at the time of tumor
inoculation. Transgenic PYMTmice were 8-13 weeks of age at the time of treatment initiation. To inoculate tumors in female C57BL/6
mice, 100,000 PYMT or PYMT-Ova tumor cells were injected into 4th mammary fat pad as specified in figure legends. Palbociclib was
administered by oral gavage at 100mg/kg once or twice per day as indicated in figure legends. Palbociclib oral solutionwas prepared
in 0.5% methylcellulose. OX-40 and 4-1BB agonistic antibodies and CD8-depleting antibody were diluted in PBS and administered
by intraperitoneal injection at 100 mg/mouse. Injections were given every 3 days for a total of 4 doses. OT-1 cells were suspended in
PBS and administered via retro-orbital injection at 8x106 cells permouse. For in vivo chemokine receptor blockade studiesmicewere
treated with 10 mg/kg CCR5i maraviroc (once a day by oral gavage) or CXCR3-blocking antibody (200 mg/mouse, intraperitoneal in-
jection every 3 days). mTORi everolimus was administered via oral gavage once a day at 5mg/kg. Mouse body weight was assessed
once a week, and tumor dimensions were measured twice a week with microcalipers (Fisherbrand Traceable). Tumor volume was
calculated as 0.5 3 length 3 width 3 width. Treatment began when tumors reached 50 to 150 mm3 volume on average. Mice
were sacrificed when tumors exceeded 15 mm in diameter or became perforated.
Cell lines
MCF7 cells were purchased from the American Type Culture Collection. Cal120, MDA-MB-453, MDA-MB-468, HCC70, and BT20
cells were provided by Carlos Arteaga. PYMT murine mammary tumor cells syngeneic to C57BL/6 mice were provided by Philip
Owens (VA Eastern Colorado Health Care System, Denver, CO). PYMT-OVA cells syngeneic to C57BL/6 mice were provided by Da-
vid DeNardo (Washington University St. Louis, St. Louis MO). Cells were cultured in Dulbecco’s modified Eagle’s medium/F12 me-
dium supplemented with 4.5g/L D-Glucose, L-Glutamine, 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin or 100x
diluted Anti-Anti mixture (all from GIBCO).
METHOD DETAILS
T cell activation and labeling
To activate T cells for ACT experiments, cells from spleens and lymph nodes of OT-1 mice were plated in 6-well plates coated with
anti-CD3e Abs (5mg/mL, overnight at +4, clone 145-2C11, Biolegend) at 2x106 cells per well and incubated further in the presence of
Continued
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Software and algorithms
ImageJ NIH Image https://imagej.nih.gov/ij/index.html
Graphpad’s Prism 7.03 software GraphPad https://www.graphpad.com/
R (version3.3.0.) Bioconductor https://www.bioconductor.org/packages/
devel/bioc/vignettes/limma/inst/doc/
usersguide.pdf
Timer version 2.0 Li et al., 2020 http://timer.cistrome.org/
Morpheus Broad Institute https://software.broadinstitute.org/
morpheus/
cBioPortal for Cancer Genomics version
3.6.3
Cerami et al., 2012 https://www.cbioportal.org/




soluble anti-CD28 Abs (3 mg/mL, 37.51, Biolegend) for two days. Next, cells were collected and re-plated at 0.25x106 cells per well
and incubated with 12.5 ng/ml of human recombinant IL-2 for another 3 days. Thirty minutes before injection into mice cells were
labeled with CellTracker Green CMFDA Dye (ThermoFisher Scientific) as recommended by the manufacturer. To block chemo-
kine-mediated trafficking, OT-1 cells were pre-treated with 100 ug/ml CXCR3-blocking antibody (clone CXCR3-173, Biolegend)
or 500nM of murine recombinant CCL5 (Peprotech) for 1 hour before injection. Two hours post injections, mice were sacrificed,
and tumors were analyzed for the presence of fluorescent cells using microscopy and flow cytometry.
Chemokine expression analysis
For mRNA expression analysis, RNA was extracted using RNA-easy mini kit (Quiagen). cDNA was prepared from 1 mg of RNA using
iScript cDNA synthesis kit (Bio-rad). We used 2 mL of cDNA as a template for Real- Time PCRwith SYBR-greenmaster mix (Molecular
Probes) and primers specific to CCL5, CXCL9, CXCL10, and b-actin purchased from Sigma. Primer sequences were obtained from
PrimerBank70 (https://pga.mgh.harvard.edu/primerbank/). For analysis of secreted chemokines, ELISA kits for humanCXCL10 (IP10)
and CCL5 (RANTES), and mouse CXCL9 and CCL5 from Peprotech (Rocky Hills, NJ) or R&D (Minneapolis, MN) were utilized as in-
structed by the manufacturer. Human chemokine array was purchased from RayBiotech (Peachtree Corners, GA).
Proteomics and western blot
Cells were pelleted by centrifugation at 15000 g and sent to Reverse Phase Protein Array (RPPA) Core Facility at MD Anderson Can-
cer Center (Houston, TX) for lysis and RPPA analysis. RPPA protein expression was compared between CDK4/6i-treated and
vehicle-treated cells using multiple t test without adjusting for multiple comparisons. Threshold for proteins that were reported as
up- or downregulated was set at the level of R 1.5-fold change and p < 0.05. MORPHEUS web tool (https://software.
broadinstitute.org/morpheus) was used for clustering of hits and heatmap plotting.
Western blot was performed as described previously (Vilgelm et al., 2017). Antibodies were purchased from Cell Signaling and
used as recommended by the vendor. Primary antibodies were applied overnight at 1:500 dilution and secondary antibody were hy-
bridized for 2 hours at 1:5000 dilutions.
Flow cytometry
For detection of immune cells, tumors were excised, dissected into small pieces, and enzymatically digested using tumor tissue
dissociation kit (Miltenyi, Germany) according to manufacturer’s recommendations. Cells were processed for viability staining
using LIVE/DEAD Fixable Aqua Dead Cell Stain Kit or eBioscience Fixable Viability Dye eFluor 780 (Thermofisher) according
to manufacturer’s instruction. Next, Fc receptor blocking was performed using Purified Rat Anti-Mouse CD16/CD32 Abs (BD bio-
sciences) for 30 min followed by staining with fluorescently labeled antibodies to immune cell surface markers. Information on
panels of antibodies, clones, fluorophores, and vendors is provided in Key resources table. For experiments where Fox3 was
evaluated, cells were processed using eBioscience Foxp3 / Transcription Factor Staining Buffer Set (Thermofisher). After stain-
ing, cells were fixed in 0.5% buffered formaldehyde and analyzed on 4-laser Fortessa (BD Biosciences) for immunophenotyping
panels, and on 5-laser Cytek Aurora (Cytek Biosciences) for T cell phenotype panel. Gating and t-SNE dimension reduction was
done using FlowJo. In a separate series of in vitro experiments, flow cytometry was utilized to determine relative cell size using
forward scatter (FSC) and cell complexity using side scatter (FSC). Amount of mitochondria were analyzed using MitoTracker
Green (Invitrogen), respectively. Intracellular ROS levels were detected using CellRox Deep Red (Invitrogen) according to man-
ufacturer’s recommendation.
Fluorescence and bright-field microscopy
IHC staining was performed by Translational Pathology Shared Resources at Vanderbilt University (Nashville, TN). MitoTracker
Green, LysoTracker Deep Red, DAPI, and CellRox Deep Red (all from Invitrogen) were used for fluorescent labeling of mitochondria,
lysosomes, nuclei, and intracellular ROS, respectively. Senescence Cells Histochemical Staining Kit (Sigma-Aldrich) was used to
detect SA-bGal-positive cells. To detect dead cells and cell DNA in live or dead cells Propidium Iodide (1mg/mL) and Hoechst
33342 (2mg/mL) were added directly into the cell media 20 minutes prior to imaging. JC-1 Mitochondrial Membrane Potential Dye
was purchased from Thermofisher and used in accordance with manufacturer’s recommendations. To visualize stained tumor sec-
tions, cell populations, and intracellular content, EVOS M5000 digital inverted microscope (Thermo Fisher Scientific, Carlsbad, CA,
USA) was utilized.
TCGA analysis
To study the association of CCL5 and CXCL10 expression with CD8+ T cell infiltration, Timer2.0 web resource for systematical anal-
ysis of immune infiltrates was used (http://timer.cistrome.org/). Expression of chemokines was correlated to CD8+ T cell infiltration
estimated by CIBERSORT-Abs., which is a score of arbitrary units that reflects the absolute proportion of each cell type derived from
computational analysis of the expression signatures of cell population of interest (Newman et al., 2015). TCGA breast cancer dataset
(BRCA) was analyzed.
To query the association of CCL5 and CXCL10 chemokine expression with breast cancer patient survival or phosphorylation of
mTOR target protein S6, cBioPortal was used (Cerami et al., 2012). TCGA Breast Invasive Carcinoma Firehose Legacy dataset




was used for analysis. Samples with CCL5 and/or CXCL10mRNA expression z-scores > 1 were categorized as high expressing, and
samples with z-cores < 1 as low-intermediate expressing.
QUANTIFICATION AND STATISTICAL ANALYSIS
Standard t test and one-way ANOVAwere used for analysis comparing two samples andmultiple samples, respectively. To study the
effect of two parameters (i.e., time and treatment) and their interaction, two-way ANOVA was applied. GraphPad’s Prism 7.03 soft-
ware and R (version 3.3.0.) were used for statistical analysis. For in vivo experiments, we compared the progression of tumor volume
(mm3) over time among groups ofmice receiving different therapywith a linearmixed-effects regressionmodel. Tomeet the normality
assumptions for these parametric methods, a square root or a natural log transformation was implemented to ameliorate the hetero-
geneity evident in the data. Mixed models estimate corrected variance estimates in the presence of correlated measurements taken
in the same mouse (such as left and right flank) and for repeated-measures on the same tumor over time. The Akaike information
criterion was used to select among competing correlation structures. Standard residual analysis and goodness-of-fit statistics
were evaluated. Survival curves were plotted and compared using GraphPad’s Prism. All tests of statistical significance were two
sided. The numbers of mice and biological relocates in experimental groups are indicated in figure legends. Animal experiments
were performed once, except for experiments combining CDK4/6i with adoptive T cell transfer (Figure 2G) and anti-OX-40/4-1BB
(Figure 2A) that were repeated twice with consistent results. In vitro experiments were repeated at least 3 times. Error bars represent
standard deviation, except for graphs showing tumor volume change over time, where error bars represent standard error.
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Table S1. Related to Figure 1. Comparison of the immune cell infiltrate in PYMT tumors from mice treated with vehicle or with CDK4/6i palbociclib (Palbo). ns 
– not significant, n/t – not tested, TAM – tumor associated macrophage, MDSC – myeloid-derived suppressor cell 
Cell population Markers (gated on 
live CD45+ cells) 
Day 8: Average 
frequency  ± SD      (% of 
CD45+) 
Day 25: Average 
frequency  ± SD    (% of 
CD45+) 







Vehicle n=9 Palbo n=9 Vehicle n=6 Palbo n=6 
B cells CD19+ 1.78 ± 0.77 3.72 ± 1.49 3.70 ± 1.95 7.17 ± 2.69 increase 0.0003 0.0003 ns 
NKT NK1.1+/CD3+ 5.05 ± 1.05 6.06 ± 1.56 3.22 ± 1.39 2.71 ± 1.22 ns 0.615 <0.0001 ns 
NK NK1.1+/CD3- 5.34 ± 2.99 5.58 ± 1.57 3.01 ± 2.41 ± ns 0.802 0.0008 ns 
T CD3+ 22.42 ± 4.52 29.35 ± 4.58 28.39 ± 9.68 41.46 ± 13.08 increase 0.002 0.005 ns 
CD4 CD4+/CD3+ 7.55 ± 1.32 8.58 ± 2.00 11.48 ± 3.08 14.31 ± 8.41 ns 0.221 0.004 ns 
LAG3 CD4 LAG3+/CD4+/CD3+ 0.72 ± 0.24 0.88 ± 0.42 1.87 ± 0.87 3.72 ± 1.31 increase 0.001 <0.0001 0.005 
TIM3 CD4 TIM3+/CD4+/CD3+ 1.08 ± 0.44 0.71 ± 0.2 2.89 ± 1.29 1.47 ± 0.90 decrease 0.003 <0.0001 ns 
CD8 CD8+/CD3+ 5.95 ± 1.53 9.17 ± 2.14 4.05 ± 1.53  7.78 ± 6.65 increase 0.01 ns ns 
LAG3 CD8 LAG3+/CD8+/CD3+ 0.78 ± 0.52 0.59 ± 0.29 1.04 ± 0.88 1.37 ± 0.57 ns 0.743 0.02 ns 
TIM3 CD8 TIM3+/CD8+/CD3+ 0.86 ± 0.63 0.84 ± 0.44 0.36 ± 0.42 0.51 ± 0.32 ns 0.63 0.029 ns 
CD11b CD11b+ 61.22 ± 9.93 55.47 ± 3.83 60.48 ± 9.35 50.48 ± 16.56 decrease 0.049 ns ns 
Macrophages/ TAM F4/80+ 13.78 ± 3.70 12.53 ± 1.46 14.45 ± 3.63 7.57 ± 2.93 decrease 0.001 ns 0.019 
CD206 
Macroph. (M2 like) 
CD206+/F4/80+ 5.25 ± 2.71 5.38 ± 1.24 4.16 ± 1.27 2.64 ± 1.11 ns 0.317 0.009 0.231 
MHCII 
Macroph. (M1 like) 
I-A/I-E+/F4/80+ 4.15 ± 1.91 3.27 ± 0.92 5.46 ± 1.74 1.95 ± 1.16 decrease 0.0005 ns 0.026 
Monocytes/ 
mMDSC 
Ly6Chigh/CD11b+ 25.83 ± 5.02 20.66 ± 2.49 22.8 ± 2.27 16.87 ± 6.15 decrease 0.002 0.04 ns 
Neutrophils/ 
gMDSC 
Ly6Ghigh/CD11b+ 1.99 ± 1.08 3.46 ± 1.36 5.89 ± 3.10 14.7 ± 4.95 increase <0.0001 <0.0001 0.001 




Supplementary Figure 1. Related to Figure 1. Palbociclib inhibits tumor growth and increases T cell infiltrate 
in transgenic PYMT model of breast cancer. A. Growth of spontaneous mammary tumors in PYMT FBV 
transgenic mice that were treated twice daily with vehicle or 100mg/kg palbociclib. Growth curves were built based 
on average volume of all fat pad tumor lesions per mouse (n=3-4 per group, mixed model, data are presented as 
mean total tumor volume ± SEM). B. Comparison of the total weight of all tumor lesions per mouse in vehicle and 
palbociclib-treated mice using t-test (n=3-4). C. Percentages of CD3+ and CD3+/CD8+ cells in tumors of mice 
shown in A (n=3-4 mice, t-test). D. Representative microphotographs and quantification of CD3 IHC staining in 
tumors of transgenic PYMT FVB mice shown in A. Several random microscopic fields were acquired. Each dot 
represents a field (n=13-16 fields, t-test). E. Representative microphotographs and quantification of FoxP3 IHC 
staining in tumors of transgenic PYMT FVB mice shown in A (n=3-4 tumors, t-test).  
 
Supplementary Figure 2. Related to Figure 1. Palbociclib affects the levels and phenotype of tumor-
infiltrating T cells and surface expression of receptors involved in tumor-immune interaction on malignant 
cells in vivo. A. Representative microphotographs and quantification of CD3 IHC staining in PYMT tumors from 
female C57Bl/6 mice treated with vehicle or 100 mg/kg palbociclib. Arrows point out infrequent CD3+ cells in 
vehicle treated group (n=5-7 individual tumors, t-test). B. Results of the dimension reduction analysis to visualize 
overall state of T cell phenotypes in tumors of vehicle and palbociclib-treated mice. These results complement 
individual parameter data shown in Fig. 1F-K. Populations of Tregs and activated CD8+ T cells are circled. C. 
Results of the flow cytometry analysis of PD-L1 expression of tumor cells from mice shown in Fig. 1F. Tumors 
were collected at 8-day time points (n=9, t-test). D. Results of the flow cytometry analysis of MHC class I 
expression on tumor cells from experiment described in Fig. 1F (n=5-6 individual tumors, t-test). 
 
Supplementary Figure 3. Related to Figure 3. Palbociclib is not cytotoxic at 0.3-10µM concentrations. MCF7 
cells were treated for 5 days with vehicle or CDK4/6i palbociclib at indicated concentrations. Control cells were 
killed by incubation in water for 10 min. Dead cells were visualized with PI and all cells were identified by hoechst 
33342 staining. A. Representative microphotographs of treated cells. B. Percentages of dead cells in indicated 
treatment groups counted in random fields (n=7 random fields, one-way ANOVA).  
 
Supplementary Figure 4. Related to Figure 3. Palbociclib induces senescence marker expression in breast 
cancer cells. A. Images of MCF7 cells cultured in the presence of 1 μM palbociclib for either 8 days or for 5 days 
followed by drug washout and additional 3 days of culture with drug vehicle only. Control cells were treated with 
vehicle for 8 days. B. Representative images of MCF7 cells treated with vehicle or 1 μM of CDK4/6i palbociclib for 
5 days and analyzed for the presence of senescence-associated β-galactosidase. C. Statistical analysis of the 
percentages of senescence-associated β-galactosidase-positive cells (n=9, t- test).  
 
Supplementary Figure 5. Related to Figure 4. Effect of combined mTOR and CDK4/6 blockade on tumor 
growth and T cell recruitment. A. cBIO portal analysis of the phosphorylation of mTOR target pS6 on residues 
S240/244 and S235/236 in human breast cancer tumors expressing high vs low-intermediate levels of CCL5 and 
CXCL10 (n=960, TCGA dataset). B. Growth of injected PYMT tumors in female c57Bl/6 mice treated once a day 
with 100 mg/kg CDK4/6i palbociclib, 5 mg/kg mTORi everolimus, combination of both or vehicle for 12 days 
(n=6-7, mixed model, error bars represent SEM). C. Final tumor weight from experiment described in B. D. Results 
of the flow cytometry analysis of CD3+ (pan-T), and CD3+CD8+ (cytotoxic T cells) cells in tumor cell suspensions 
from PYMT tumor-bearing C57Bl/6 mice treated with 100 mg/kg CDK4/6i palbociclib, 5 mg/kg mTORi 
everolimus, combination of both, or vehicle for 8 days. Cells were gated on live cells based on viability dye staining 
(n=3-6, one-way ANOVA). E. Numbers of MCF7 cells treated with 2µM mTOR inhibitor rapamycin (mTORi), 
5µM CDK4/6i palbociclib, or combination of both for 5 days. Cells were counted in random microscopic fields after 
crystal violet staining (n=6, t-test).  F. Representative microphotographs of cells from experiment in E. 
